Redoxis R&D activities

Redoxis founders and personel have a strong background in academic research on animal models of inflammation and autoimmunity with focus on redox regulation of the immune system. Redoxis was founded as a R&D company with focus on development of small molecules targeting the NOX2 complex (phagocytic NADPH oxidase) for treatment of autoimmune conditions. That project is since May 2016 continued in our subsidiary ProNoxis. As a company we value connection with the academic research and engage in both research programmes and activities including exchange of personel between academic and industrial institutions. This connection and active works within the academic research field help us keep up to date with the recent findings and continue development of services provided. We are continuously increasing and refining the models we are providing, with the aim of being a reliable and cost efficient provider of preclinical models of autoimmunity and inflammation.

Example of our latest publications: 

Wallner et al. Correlation and cluster analysis of immunomodulatory drugs based on cytokine profiles (2018) Pharmacol Res. '

Wallner et al. Cytokine correlation analysis based on drug perturbation (2017) Cytokine. 

Tuncel et al. Animal models of Rheumatoid Arthritis (I): Pristane-Induced Arthritis in rats (2016) PLoS One. 

Guerard et al. The SKG Mutation in ZAP-70 also Confers Arthritis Susceptibility in C57 Black Mouse Strains (2016) Scand J Immune

Winter et al. A Reduction in Intracellular Reactive Oxygen Species Due to a Mutation in NCF4 Promotes Autoimmune Arthritis in Mice (2016) Antioxid Redox Signal

Hultqvist et al. Pharmacological Potential of NOX2 Agonists in Inflammatory Conditions (2015) Antioxid Redox Signal

Kelkka et al. Reactvie oxygen species deficiency induces autoimmunity with type 1 interferon signature (2014) Antioxid Redox Signal 

EU funded research projects

We value the connection to academic research and we aim to always expand and improve our knowledge and service portfolio. We are therefore happy to be part of several EU funded research programs. Our currently ongoing project are:


IMAID (Advanced in vivo imaging service for preclinical models to improve therapies in Autoimmune Diseases) is a Eurostars project where we together with Image analysis (UK) and LBIC (Lund University, Lund) aim to set up and provide services of advanced in vivo imaging analysis in preclinical animal models of autoimmune conditions for the pharmaceutical industry. We hope that inclusion of in vivo imaging of joint and CNS pathologies in whole animals will provide a more detailed and extensive evaluation of efficacy of new drugs and improve the selection of the best drugs for further development and clinical trials. The IMAID project (E!9215) was finalised in March 2018. 


A RISE program (Marie Sklodowska-Curie Action) aiming at transfer of knowledge and networking between Aston University (Aston, UK), Friedrich-Alexander University (Erlangen, DE) and Redoxis (SE). The project targets reactive oxygen species (ROS) mediated regulation of immunology and aging. It brings together the application of small molecule candidate drugs to generate ROS using innovative approaches to biomarker identification in models of chronic immune disease. 


COSMIC is a European Training Network funded from the European Union's Horizon 2020 research and innovation programme (grant agreement NO 765158). COSMIC (Combating disorders of adaptive immunity with systems medicine) is an international consortium coordinated byt he Academic Medical Center in Amsterdam and will deliver 14 next generation systems medicine professionals. COSMIC aims ot contribute to the European systems medicine infrastructure through collaboration with existing initiatives and by contributing to best practices that reduce time and cost to address clinical needs.